Navigation Links
Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference

CORAL GABLES, Fla., Feb. 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that it will be making a presentation today at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum being held at the Hyatt Embarcadero Hotel in San Francisco.  For additional program information, please visit  As previously reported, the Company will present an overview of CPP-115, Catalyst's development stage anticonvulsant compound, as a potential treatment for a variety of epileptic conditions, including complex partial seizures and infantile spasms (West Syndrome). Further, the Company reported that its presentation materials from the conference are now posted on the Company's website,, under "Events and Presentations."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. The Company has obtained from Brookhaven National Laboratory an exclusive license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also in-licensed worldwide rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. CPP-109, Catalyst's version of vigabatrin, has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction.  Catalyst has recently in-licensed worldwide rights to another patented drug, CPP-115, from Northwestern University. The Company intends to pursue development of CPP-115 for several indications, including epilepsy and drug addiction.  For more information about the Company, go to

SOURCE Catalyst Pharmaceutical Partners

Back to top



SOURCE Catalyst Pharmaceutical Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... , November 30, 2015 ... or the "Company") announced today that it was informed by ... and Drug Safety (MFDS) has approved its Exablate Neuro ... --> --> Insightec,s Exablate ... treatment alternative that combines two technologies: Focused Ultrasound, which ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... Cycling, running, and walking are regular Sunday activities for many South ... 28, 2016. , That’s when the 7th annual ANF Group Tour de Broward ... and families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... ingredient list of its hemorrhoid ointment to its website. , “Our goal is ... people suffering from hemorrhoids. Adding the comparison chart and ingredient list allows our ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their priority is ... When you have dental problems, you need to turn to a dentist who listens ... treat your needs, a friendly dentist who counsels you on the best ways to ...
(Date:11/30/2015)... ... ... Dr. Seth D. Margulies specializes in orthodontics and is based in Perth ... the best available orthodontic experience in the area. Dr. Margulies has met all ... the branch of dentistry that specializes in the diagnosis, prevention, and treatment of dental ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... new study by UPMC and KingMed Diagnostics researchers. Their ... years found that consultation with UPMC pathologists resulted in significantly altered treatment plans ...
Breaking Medicine News(10 mins):